Variables |
No-Ex |
Low-Ex |
High-Ex |
p value |
n |
20 |
27 |
33 |
|
Within days following fibreoptic bronchoscopy |
Within days following
fibreoptic bronchoscopy |
Within days following fibreoptic bronchoscopy |
Within days following fibreoptic bronchoscopy |
Within days following
fibreoptic bronchoscopy |
Patients treated by ATB |
9/20 (45.0) |
21/27 (77.8) |
23/33 (69.7) |
<0.001a,b |
Pathogenic bacteria treated by ATB |
9/11 (81.8) |
21/26 (80.8) |
23/26
(88.4) |
0.730 |
During the 12 months following fibreoptic bronchoscopy |
During the 12
months following fibreoptic bronchoscopy |
During the 12 months
following fibreoptic bronchoscopy |
During the 12 months following
fibreoptic bronchoscopy |
During the 12 months following fibreoptic
bronchoscopy |
≥1 Hospitalization for wheeze |
0/20 (0.0) |
6/27 (22.2) |
21/33 (63.6) |
<0.001a,b,c |
≥1 ED visit for wheeze |
0/20 (0.0) |
10/27 (37.0) |
14/33 (42.4) |
0.003a,b |
Increased daily dose of ICS |
0/20 (0.0) |
2/27 (7.4) |
16/33 (48.5) |
<0.001b,c |
Unchanged daily dose of ICS |
9/20 (45.0) |
15/27 (55.6) |
14/33 (42.4) |
|
Decreased daily dose of ICS |
11/20 (55.0) |
10/27 (37.0) |
3/33 (9.0) |
|
12 months after fibreoptic bronchoscopy, number of patients treated with |
12 months after fibreoptic bronchoscopy, number of patients treated
with |
12 months after fibreoptic bronchoscopy, number of patients
treated with |
12 months after fibreoptic bronchoscopy, number of
patients treated with |
12 months after fibreoptic bronchoscopy, number
of patients treated with |
ICS |
19/20 (95.5) |
26/27 (96.3) |
33/33 (100.0) |
0.468 |
Leukotriene receptor antagonists |
15/20 (75.0) |
23/27 (85.2) |
30/33 (90.9) |
0.290 |
Long-acting beta-agonists |
11/20 (55.0) |
9/27 (33.3) |
15/33 (45.5) |
0.323 |
Antihistamine agents |
8/20 (40.0) |
9/27 (33.3) |
15/33 (45.5) |
0.635 |
ATB= antibiotics; ICS= inhaled corticosteroids; eq. = equivalent,
ED = Emergency department.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)); Comparisons between
groups were performed using Kruskal-Wallis tests with Dunn’s post-tests
for quantitative variables and Chi-square tests for categorical
variables. Statistical significance (bold): p<0.05
(a p<0.05 for No-Ex vs Low-Ex;
b p<0.05 for No-Ex vs High-Ex;
c p<0.05 for Low-Ex vs
High-Ex).
|
ATB= antibiotics; ICS= inhaled corticosteroids; eq. = equivalent,
ED = Emergency department.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)); Comparisons between
groups were performed using Kruskal-Wallis tests with Dunn’s post-tests
for quantitative variables and Chi-square tests for categorical
variables. Statistical significance (bold): p<0.05
(a p<0.05 for No-Ex vs Low-Ex;
b p<0.05 for No-Ex vs High-Ex;
c p<0.05 for Low-Ex vs
High-Ex).
|
ATB= antibiotics; ICS= inhaled corticosteroids; eq. = equivalent,
ED = Emergency department.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)); Comparisons between
groups were performed using Kruskal-Wallis tests with Dunn’s post-tests
for quantitative variables and Chi-square tests for categorical
variables. Statistical significance (bold): p<0.05
(a p<0.05 for No-Ex vs Low-Ex;
b p<0.05 for No-Ex vs High-Ex;
c p<0.05 for Low-Ex vs
High-Ex).
|
ATB= antibiotics; ICS= inhaled corticosteroids; eq. = equivalent,
ED = Emergency department.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)); Comparisons between
groups were performed using Kruskal-Wallis tests with Dunn’s post-tests
for quantitative variables and Chi-square tests for categorical
variables. Statistical significance (bold): p<0.05
(a p<0.05 for No-Ex vs Low-Ex;
b p<0.05 for No-Ex vs High-Ex;
c p<0.05 for Low-Ex vs
High-Ex).
|
ATB= antibiotics; ICS= inhaled corticosteroids; eq. = equivalent,
ED = Emergency department.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)); Comparisons between
groups were performed using Kruskal-Wallis tests with Dunn’s post-tests
for quantitative variables and Chi-square tests for categorical
variables. Statistical significance (bold): p<0.05
(a p<0.05 for No-Ex vs Low-Ex;
b p<0.05 for No-Ex vs High-Ex;
c p<0.05 for Low-Ex vs
High-Ex).
|